

Jordan

COUNTRY GENERAL INFORMATION

Total population:	9 965 322
Gender F/M (%):	49.4 / 50.6
Population, age group <15 / ≥ 15 years (%):	34 / 66
Life expectancy at birth (F/M, years):	79 / 77
GDP (PPP int \$):	9348
Income status:	Upper middle income
Number of 2 nd sub-national administrative level divisions, name:	21, District



EPIDEMIOLOGY

	VL	CL	ACL	ZCL
Endemicity status:	Endemic	Endemic	No data	No data
Number of new cases (incidence):	2	154	N/A	N/A
Number of relapses: ¹	No data	0	N/A	N/A
Total number of cases:	2	154	N/A	N/A
Imported cases (#, %):	1, 50%	4, 3%	No data	No data
Gender distribution (% F):	50	32	N/A	N/A
Age group distribution (% , <5 / 5-14 / >14):	50 / 0 / 50	12 / 38 / 50	N/A	N/A
Incidence rate (cases/10 000 population in endemic areas):	0.04	0.63	No data	No data
Number of endemic 2 nd sub-national administrative level divisions:	2	11	No data	No data
Population at risk (% , # at risk / total population): ²	5% 501 880/ 9 965 322	25% 2 459 070/ 9 965 322	0% 0/ 9 965 322	0% 0/ 9 965 322
Was there any outbreak?	No	No	N/A	N/A
Number of new foci: ³	1	0	N/A	N/A



Monthly distribution of new cases (January-December)

2018	JAN	FEB	MAR	APR	MAY	JUN	JUL	AUG	SEP	OCT	NOV	DEC
VL	0	0	0	0	0	0	0	0	0	2	0	0
CL	3	4	8	15	10	1	9	12	6	24	20	42

N/A not applicable; VL = visceral leishmaniasis; CL = cutaneous leishmaniasis; ACL = anthroponotic cutaneous leishmaniasis; ZCL = zoonotic cutaneous leishmaniasis



Number of new cases and Incidence rate/10 000 at the national level from 2003 to 2018




¹Relapse in this country is defined as: no definition available;

²Defined as "Number of people living in 2nd sub-national administrative level endemic areas"

³Defined as "In this reporting period, an area at the 2nd sub-national administrative level reporting cases for the first time ever"

Disease distribution of new VL and CL cases at District level per 10 000 population (2018)



The boundaries and names shown and the designations used on this map do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.
Map production: WHO/UCN/NTD

CONTROL AND SURVEILLANCE

Year Leishmaniasis National Control Programme (LNCP) was established:	No data
Type of surveillance (CL / VL):	Integrated / Integrated
Is there a vector control programme?	Yes
Type of insecticide used for Indoor residual Spraying (IRS):	Deltamethrin
Year latest national guidelines (CL / VL):	2010 / No data
Is leishmaniasis notifiable (mandatory report)? (CL / VL):	Yes / Yes
Is there a reservoir host control programme?	No
Number of leishmaniasis health facilities (CL / VL):	0 / No data

DIAGNOSIS

	VL	CL	ACL	ZCL
Number of people screened actively for:	0	35	N/A	N/A
Number of people screened passively for:	No data	No data	No data	No data
VL cases diagnosed by RDT (% , # RDT+ / new VL cases):	0% (0/2)	N/A	N/A	N/A
Proportion of positive RDT (% , # RDT+ / total RDT):	No data	N/A	N/A	N/A
Cases diagnosed by direct exam (parasitology) (% , # slides + / total cases):	100% (2/2)	3% (5/154)	N/A	N/A
Proportion of positive slides (% , # slides + / total slides):	100% (2/2)	25% (5/20)	No data	No data
Cases diagnosed clinically (% , # clinical cases / total cases):	0% (0/2)	97% (149/154)	N/A	N/A
Percentage of cases with HIV-VL coinfection:	No data	N/A	N/A	N/A

N/A not applicable; RDT = rapid diagnostic test; HIV = human immunodeficiency virus

TREATMENT AND MEDICINES

- ▶ Is treatment provided for free in the public sector? (CL / VL): Yes / Yes
- ▶ Antileishmanial medicines included in the National Medicine List: Sodium stibogluconate (SSG)

INITIAL TREATMENT OUTCOME FOR NEW CASES

	VL	CL	ACL	ZCL
Cases that completed treatment (% , # completed treatment / new cases):	50% (1/2)	No data	N/A	N/A
Initial cure rate (% , # cases initially cured / new cases):	50% (1/2)	No data	N/A	N/A
Failure rate (% , # cases with treatment failure / new cases): ⁴	0% (0/2)	No data	N/A	N/A
Case fatality rate (% , # cases who died / new cases):	50% (1/2)	No data	N/A	N/A

VL = visceral leishmaniasis; CL = cutaneous leishmaniasis; ACL = anthroponotic cutaneous leishmaniasis; ZCL = zoonotic cutaneous leishmaniasis

⁴Failure in this country is defined as: no definition available